Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Cost Effectiveness of Adjuvant Pembrolizumab after Nephrectomy for High Risk Renal Cell Carcinoma: Insights for Patient Selection from a Markov ModelJ Urol 2022 Sep 06;[EPub Ahead of Print], V Sharma, KM Wymer, DD Joyce, J Moriarty, A Khanna, BJ Borah, RH Thompson, BA Costello, BC Leibovich, SA Boorjian
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.